A condition is classified as rare when it affects fewer than 200,000 people in the US (or 1 in 2,000 in Europe). That threshold creates a commercial problem for drug development — the potential patient population is too small to justify the cost of standard drug development economics. The result: most rare diseases have no approved treatment, and the research pipeline is driven largely by academic centers, rare disease foundations, and government funding rather than large pharmaceutical companies.
This shapes everything about how you search for and access trials.
Where to search — beyond ClinicalTrials.gov
NORD (National Organization for Rare Disorders) maintains a database at rarediseases.org that includes trials, patient registries, and connecting resources. For many rare conditions, NORD is a more curated starting point than the general database.
Orphanet is the European equivalent — a comprehensive rare disease reference that includes research and trial listings. If you're in Europe or willing to travel internationally, Orphanet often surfaces trials that don't appear prominently in ClinicalTrials.gov.
Condition-specific foundations. For most named rare diseases, there's an organization — usually founded by patients and families — that tracks every trial globally. These foundations often have direct relationships with the research teams and can help navigate eligibility and access. Find the one for your condition and contact them directly.
Academic medical centers with rare disease programs. Centers like NIH Clinical Center (Bethesda), Mayo Clinic, Mass General, and their international equivalents run rare disease programs that aren't always prominently advertised. Calling the rare disease or genetics department directly is often more productive than database searching.
Natural history studies: why they matter even without treatment
For the rarest conditions, there may be no treatment trial open anywhere. But natural history studies — observational studies that document how a disease progresses in a defined population — may be recruiting. These are worth joining even without a treatment option, for two reasons.
First, they generate the foundational data that makes treatment trials possible. If researchers don't understand the natural course of your disease, they can't design a trial that measures whether a treatment changes it. Participating in a natural history study is a genuine contribution to future treatment development.
Second, participants in natural history studies are often the first contacted when a treatment trial opens. Being in the database puts you ahead of the general search process.
Compassionate use and expanded access
If there's a drug that's completed Phase 2 or 3 trials for your condition but hasn't yet received regulatory approval, it may be available through an expanded access (compassionate use) program. This isn't a trial — you don't contribute to research data — but it provides access to a treatment that's shown promise.
Expanded access is requested by your physician through the sponsor and then approved by the FDA (in the US) or national authority elsewhere. Ask your physician whether this applies to any compound currently in development for your condition.
Travel is often unavoidable
Rare disease trials frequently run at a single site — the academic center that leads the research. This means travel, sometimes internationally, is part of the reality. Some sponsors provide travel reimbursement or even accommodation stipends specifically because they understand the access problem. Ask explicitly about travel support before self-excluding on geographic grounds.